ASAH1 and lung carcinoma: Tamoxifen, which we confirmed to inhibit ASAH1 activity, has also been shown to be active in combination with cisplatin against nonsmall‐cell lung cancer.18 This is in agreement with the 2019 study that showed a significant reduction in colonies following treatment of cisplatin‐generated A549 lung cancer PGCC with the ASAH1 inhibitor LCL521.13